Interleukin-15 and its soluble receptor mediate the response to infliximab in patients with Crohn's disease.

@article{Bouchaud2010Interleukin15AI,
  title={Interleukin-15 and its soluble receptor mediate the response to infliximab in patients with Crohn's disease.},
  author={G Bouchaud and Erwan Mortier and Mathurin Flamant and Isabelle Barbieux and Ariane Plet and J. -P. Galmiche and Yannick Jacques and A Bourreille},
  journal={Gastroenterology},
  year={2010},
  volume={138 7},
  pages={2378-87}
}
BACKGROUND & AIMS Infliximab is a monoclonal antibody against tumor necrosis factor that is used to treat patients with inflammatory bowel disease. We investigated serum levels and cellular expression of interleukin (IL)-15 and its receptor (sIL-15Ralpha) in patients with Crohn's disease (CD) treated with infliximab; and the effect on sIL-15Ralpha secretion… CONTINUE READING